Martin ZapataLaguado· @zapatalaguadomd · X·· 2 天前评分45
正文 · 原文
#ESMO26 | TALAPRO-3: Patient-reported outcomes comparing talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC.
An important perspective on quality of life with PARP inhibitor combinations.
@SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily
36 浏览 · 0 赞 · 1 转发 · 0 回复
会议摘要
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.org来源：Martin ZapataLaguado · x.com